HAVCR2 and neoplasm: Combination therapy did not affect the proportion of PD-1+ CD8+ T cells but reduced the frequency of CTLA-4+ and Tim-3+ CD8+ T cells as compared to the tumor-bearing group (Figure S7D–F).